Loading clinical trials...
Loading clinical trials...
Prevention of HBV Reinfection After Liver Transplantation Using Entecavir Monotherapy After Short-term HBIg Administration: A Pilot Study
The purpose of this study is to determine whether hepatitis B immunoglobin can be discontinued early after hepatitis B virus (HBV) induced liver transplantation and be replaced by the nucleoside analogue entecavir to prevent hepatitis B reinfection.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University Clinic Essen
Essen, Germany
Hannover Medical School
Hanover, Germany
University Hospital Heidelberg
Heidelberg, Germany
Start Date
March 1, 2008
Primary Completion Date
June 1, 2014
Completion Date
October 1, 2014
Last Updated
November 5, 2014
20
ESTIMATED participants
Entecavir
DRUG
Lead Sponsor
HepNet Study House, German Liverfoundation
Collaborators
NCT07480057
NCT07024641
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07237750